DOCSLIB.ORG

Angle AGL Pharmaceuticals and Biotechnology — GBP 1.21 at Close 14 May 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Angle AGL Pharmaceuticals and Biotechnology — GBP 1.21 at Close 14 May 2021 FTSE COMPANY REPORT Share price analysis relative to sector and index performance Angle AGL Pharmaceuticals and Biotechnology — GBP 1.21 at close 14 May 2021 Absolute Relative to FTSE UK All-Share Sector Relative to FTSE UK All-Share Index PERFORMANCE 14-May-2021 14-May-2021 14-May-2021 1.3 250 160 1D WTD MTD YTD 1.2 150 Absolute 6.6 6.6 3.9 153.4 Rel.Sector 6.0 5.5 2.2 140.7 1.1 140 Rel.Market 5.4 8.0 3.1 132.0 200 130 1 120 0.9 VALUATION 110 0.8 150 100 Trailing Relative Price Relative 0.7 Price Relative 90 PE -ve 0.6 Absolute Price (local currency) (local Price Absolute 80 100 EV/EBITDA -ve 0.5 70 PB 8.3 0.4 60 PCF -ve 0.3 50 50 Div Yield 0.0 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 Price/Sales +ve Absolute Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Net Debt/Equity 0.1 100 100 100 Div Payout 0.0 90 90 90 ROE -ve 80 80 80 70 Index) Share 70 Share Sector) Share - - 70 60 60 DESCRIPTION 60 50 50 50 The principal activity of the Company is 40 40 RSI RSI (Absolute) 40 commercialising a platform technology that can 30 30 capture cells circulating in blood which are related to 20 30 20 cancer diagnostics and foetal health. 10 20 10 RSI (Relative to FTSE UKFTSE All to RSI (Relative RSI (Relative to FTSE UKFTSE All to RSI (Relative 0 10 0 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 Past performance is no guarantee of future results. Please see the final page for important legal disclosures. 1 of 4 FTSE COMPANY REPORT: Angle 14 May 2021 Valuation Metrics Price to Earnings (PE) EV to EBITDA Price to Book (PB) 30-Apr-2021 30-Apr-2021 1 9 0.9 8 0.8 0.7 7 +1SD 0.6 6 0.5 Avg 0.4 5 0.3 4 -1SD 0.2 3 0.1 0 ‖ ‖ 2 May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 PureTech Health 120.0 Oxford Biomedica 100.0 Indivior 18.6 Dechra Pharmaceuticals 120.0 Genus 36.5 AstraZeneca 8.9 Genus 81.7 Dechra Pharmaceuticals 31.5 Angle 8.3 AstraZeneca 40.9 AstraZeneca 20.8 Oxford Biomedica 8.0 Pharmaceuticals and Biotechnology 21.6 Pharmaceuticals and Biotechnology 12.7 Dechra Pharmaceuticals 6.8 Hikma Pharmaceuticals 16.8 Hikma Pharmaceuticals 11.8 Genus 6.5 GlaxoSmithKline 11.7 Vectura Group 10.9 Pharmaceuticals and Biotechnology 6.3 Vectura Group 5.5 GlaxoSmithKline 8.1 GlaxoSmithKline 4.6 Indivior -9.8 Indivior 7.9 Hikma Pharmaceuticals 3.6 Angle -27.2 PureTech Health 0.0 PureTech Health 2.4 Oxford Biomedica -120.0 Angle 0.0 Vectura Group 1.2 -150 -100 -50 0 50 100 150 0 20 40 60 80 100 120 0 2 4 6 8 10 12 14 16 18 20 Price to Cash Flow (PCF) Dividend Yield % Price to Sales (PS) 30-Apr-2021 30-Apr-2021 1 16 ‖ ‖ 0.9 14 0.8 12 0.7 0.6 10 0.5 8 0.4 6 0.3 4 0.2 0.1 2 0 0 May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 Oxford Biomedica 80.0 GlaxoSmithKline 6.0 Angle 15.0 Genus 48.5 Pharmaceuticals and Biotechnology 3.7 PureTech Health 15.0 Dechra Pharmaceuticals 40.8 AstraZeneca 2.7 Oxford Biomedica 10.2 AstraZeneca 27.0 Hikma Pharmaceuticals 1.5 Dechra Pharmaceuticals 8.5 Vectura Group 26.9 Dechra Pharmaceuticals 0.9 Genus 6.0 Hikma Pharmaceuticals 16.8 Genus 0.6 AstraZeneca 4.9 Pharmaceuticals and Biotechnology 15.8 Vectura Group 0.0 Vectura Group 3.5 GlaxoSmithKline 8.8 PureTech Health 0.0 Pharmaceuticals and Biotechnology 3.2 Indivior -7.5 Oxford Biomedica 0.0 Hikma Pharmaceuticals 3.1 PureTech Health -11.6 Indivior 0.0 Indivior 2.2 Angle -36.0 Angle 0.0 GlaxoSmithKline 2.0 -60 -40 -20 0 20 40 60 80 100 0 1 2 3 4 5 6 7 0 2 4 6 8 10 12 14 16 Note: bar chart reflects the top and bottom five current values for the valuation ratio in question for FTSE All Shares stocks in the same sector as the stock concerned. All valuation metrics are trailing. 2 of 4 FTSE COMPANY REPORT: Angle 14 May 2021 Valuation Metrics Net Debt to Equity Dividend Payout (DP) Return on Equity (RoE) 30-Apr-2021 30-Apr-2021 0.061 1 0.9 0.9 0.05 0.8 0.8 0.7 +1SD 0.7 0.04 0.6 0.6 0.030.5 0.5 0.4 0.4 0.02 0.3 Avg 0.3 0.2 0.2 0.01 0.1 0.1 0 ‖ ‖ ‖ ‖ 0 May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 Indivior 3.5 AstraZeneca 100.0 GlaxoSmithKline 44.2 GlaxoSmithKline 1.9 Dechra Pharmaceuticals 100.0 Pharmaceuticals and Biotechnology 31.8 Pharmaceuticals and Biotechnology 1.5 Pharmaceuticals and Biotechnology 80.5 Vectura Group 25.4 AstraZeneca 1.3 GlaxoSmithKline 69.3 AstraZeneca 23.2 Dechra Pharmaceuticals 0.6 Genus 46.7 Hikma Pharmaceuticals 21.1 Hikma Pharmaceuticals 0.4 Hikma Pharmaceuticals 26.7 Genus 8.0 Genus 0.3 Vectura Group 0.0 Dechra Pharmaceuticals 5.9 Oxford Biomedica 0.1 PureTech Health 0.0 PureTech Health 0.9 PureTech Health 0.1 Oxford Biomedica 0.0 Oxford Biomedica -6.6 Angle 0.1 Indivior 0.0 Angle -39.4 Vectura Group 0.0 Angle 0.0 Indivior -50.0 0 0.5 1 1.5 2 2.5 3 3.5 4 0 20 40 60 80 100 120 -60 -40 -20 0 20 40 60 ROE vs. PB — sector Du Pont Analysis 20 2 1.2 18 INDV 0 1 16 -2 14 -4 0.8 12 -6 0.6 PB 10 -8 AZN AGL 8 OXB -10 0.4 DPH GNS Pharmaceuticals 6 -12 GSK 0.2 4 HIK -14 PRTC 2 -16 0 VEC 2017 2018 2019 2020 2021 0 0 5 10 15 20 25 30 35 40 45 50 Net Margin Asset Turnover Gearing ROE (rhs) ‖ ROE Note: bar chart reflects the top and bottom five current values for the valuation ratio in question for FTSE All Shares stocks in the same sector as the stock concerned. All valuation metrics are trailing. 3 of 4 FTSE COMPANY REPORT: Angle 14 May 2021 Brief description Brief description Price to Earnings Price to Earnings (PE) is price over earnings per share. Earnings are based on the latest Gearing Gearing is Total Assets divided by Common Equity. Total Assets and Common Equity are (PE) available fiscal year earnings. each averaged over two years, that is, t and (t-1). Price to Sales (PS) Price to Sales (PS) is price divided by sales per share. It is based on sales from continuing Asset Turnover Asset turnover is Sales divided by Total Assets. Total Assets is averaged over two years, operations for the fiscal year. that is, t and (t-1). Price to Book (PB) Price to Book (PB) is price at the indicated date divided by common equity per share. Dupont Breakdown Return on Equity (RoE) = Net Margin * Gearing * Asset Turnover Common/ordinary equity is generally as reported at the most recent fiscal year-end but is Analysis adjusted to exclude minority interest, preferred stock and selected items as appropriate. RoE vs PB Plot of RoE versus PB at last month end for all FTSE UK All Share stocks in the sector Price to Cash Flow Price to Cash Flow (PCF) is price at the indicated date divided by cash flow per share. relative to the stock in question. Data may be limited to the stock in question if there are (PCF) currently no stocks in the corresponding FTSE UK All Share sector. Net Debt Equity Net Debt Equity is Net Debt as a percentage of common equity. Not calculated if Absolute Absolute graphs reflect performance for the stock in question for up to 366 days adjusted denominator (common equity) is negative for intervening corporate actions. EV to EBITDA EV to EBITDA is Enterprise Value divided by EBITDA (Earnings before Interest and Taxes, Relative Relative charts reflect the performance for the stock in question relative to the depreciation and amortisation). EV is full company Market Capitalisation at the data date corresponding sector of the FTSE All Share Index for up to 366 days, rebased to the start plus last annual net debt and Preferred Stock. Net Debt is total financial debt less cash date. Note that the stock itself may not be a FTSE All share constituent. Relative Chart and short-term investments. EBITDA is operating income plus depreciation and may be null if there are no stocks in the corresponding FTSE UK All Share sector. amortisation. RSI Relative Strength Index.
Load more

Recommended publications
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Cboe UK Healthcare Sector Index BUKHLTH
    Cboe UK Healthcare Sector Index BUKHLTH Page 1 August 2021 Cboe Exchange This sector represents products and services that are designed, developed, and utilized in the promotion of health and well-being, including medical services, health plans, medical devices, and biopharmaceuticals. The parent index is the Cboe UK All Companies (BUKAC). The index base level is 10,000 as of December 31st, 2010. This is a price return index. Objective The index is designed for use in the creation of index tracking funds, derivatives and as a performance benchmark. Investability Liquidity Transparency Availability Stocks are selected and Stocks are screened to Uses a transparent, rules-based Calculation is based on weighted to ensure that the ensure that the index is construction process. Index price and total return index is investable. tradable. Rules are freely available on the methodologies, both real cboe.com/europe/indices -time, intra-second and website. end of day. Statistics Index ISIN Ticker RIC Currency Cboe UK Healthcare Sector DE000SLA1DJ6 BUKHLTH .BUKHLTH GBP Cboe UK Healthcare Sector - net DE000SLA18F5 BUKHLTHN .BUKHLTHN GBP Volatility Volatility (1y) 0.1776 Returns(%) 1M 3M 6M YTD 1Y 3Y 5Y BUKHLTH 2.03 2.35 16.31 7.02 -2.85 13.78 17.14 BUKHLTHN 2.97 3.33 18.35 10.28 0.52 26.24 39.74 Top 5 Performers Country 1 month return % INDIVIOR PLC UNITED KINGDOM 17.70 MEDICLINIC INTERNATIONAL PLC UNITED KINGDOM 12.80 OXFORD BIOMEDICA PLC UNITED KINGDOM 11.38 PURETECH HEALTH PLC UNITED KINGDOM 8.77 VECTURA GROUP PLC UNITED KINGDOM 7.76 Historical Performance Chart 100% 80% 60% 40% 20% 0% 2011 2013 2014 2016 2017 2018 2020 2021 Cboe UK Healthcare Sector (GBP) Cboe UK All Companies (GBP) Cboe.com | ©Cboe | /CboeGlobalMarkets | /company/cboe © 2021 Cboe Exchange, Inc.
    [Show full text]
  • March 2018 1 MARKET UPDATE| HEALTHCARE
    MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE March 2018 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, 2017 ended with the $69 billion CVS Health / Aetna deal. Pharmacy +6.5% Benefit Manager (PBM) consolidation took another major step this month 5Y-CAGR with Cigna scooping up the largest independent PBM, Express Scripts, in a $52 billion deal. Additionally, rumor has it that Walmart is in the early Worldwide stages talks with insurer Humana, looking at a variety of options including prescription drugs - an acquisition. The frenzy might very well be due to Amazon’s debut in expected sales healthcare and the looming shadow of its entrance in the pharmacy market. But Amazon is also putting pressure on consumer care products, intensifying price competition. In response, pharmaceuticals groups are +5.3% parted between those which want to hold on to these products that are 5Y-CAGR generally durable brands with loyal customers, and others which doubt Medtech market - their long-term stable returns. GlaxoSmithKline had us hold our breath: expected growth after entering - and eventually quitting - the race to buy Pfizer’s consumer healthcare business for a price tag hoped to be as much as $20 billion, the company bought Novartis out of their consumer healthcare joint venture for $13 billion. GSK is thus taking full control of products -0.7%/-2.2% including Sensodyne toothpaste, Panadol headache tablets and muscle gel Monthly EU Pharma & Voltaren. biotech performance March was also home to remarkable market transactions in the biotech and medtech fields that had us quite excited, beyond the fact that Bryan, Garnier & Co.
    [Show full text]
  • RCP BIA 2020 Review January 2021 FINAL.Pdf
    UK BioIndustry Association UK Listed Biotech & Life Sciences 2020 – Year in Review– May you live in interesting times Radnor Broad UK Listed Biotech Index - 2 Year Chart Unweighted Weighted FTSE All-Share 350 300 250 200 150 100 50 Dec '20 Dec Dec '18 Dec '19 Mar '19 Jun '19 Sep '19 Dec '20 Mar '20 Jun '20 Sep Source: FactSet, Radnor 2020 has been an extraordinary year across the market but there is no doubt that the UK listed biotech sector has been in the front line in more ways than one. Investors have clearly responded to both the efforts made by the sector to combat the pandemic, but also the structural growth opportunity within biotech that the pandemic has bought into sharper focus. Not only have we seen headline share price underperformance reverse sharply through the course of 2020, but critically, the pace and scale of sector fundraising activity has stepped up materially. Perhaps most importantly, the number of investors active in the sector (institutional, private wealth, individual and overseas) have expanded. This feature alone has gone a long way towards addressing one of the key issues facing the sector. The BioIndustry Association ▪ Sector Outperformance. 2020 has been the strongest period of price is a research client of Radnor outperformance over the last 10 years. Interestingly, this outperformance has Capital Partners Ltd. been delivered across all the sub-indices making up the Broad Biotech index; although performance levels have varied somewhat. This outperformance has MiFID II – this research is also been much more pronounced then looking at the sector on an equal deemed to be a minor, non- monetary benefit.
    [Show full text]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
    [Show full text]
  • Brown Capital Management International Small Company Fund Schedule of Investments As of December 31, 2020 (Unaudited)
    7 Brown Capital Management International Small Company Fund Schedule of Investments As of December 31, 2020 (Unaudited) Shares Value (Note 1) COMMON STOCKS - 96.60% Australia - 6.06% 708,305 REA Group, Ltd. $ 81,287,705 1,464,269 WiseTech Global, Ltd. 34,713,030 116,000,735 Austria - 0.72% 364,651 Schoeller-Bleckmann Oilfield Equipment AG 13,854,217 Canada - 8.81% (a) 1,493,328 Descartes Systems Group, Inc. 87,342,501 (a) 574,515 Kinaxis, Inc. 81,395,267 168,737,768 Denmark - 8.36% 1,718,159 Ambu A/S - Class B 74,226,815 1,231,585 NNIT A/S 24,581,567 412,166 SimCorp A/S 61,259,325 160,067,707 France - 10.09% 1,499,660 Albioma SA 86,106,283 12,180 Esker SA 2,627,739 1,167,698 Interparfums SA 61,268,589 1,412,713 Lectra 43,145,760 193,148,371 Germany - 13.03% (a) 2,470,144 Evotec SE 91,373,934 1,216,343 Nexus AG 75,782,759 548,366 STRATEC SE 82,264,614 249,421,307 Hong Kong - 3.55% 16,666,000 Kingdee International Software Group Co., Ltd. 67,932,795 India - 1.37% 588,229 CRISIL, Ltd. 15,469,415 1,862,265 Emami, Ltd. 10,800,079 26,269,494 Ireland - 1.34% 125,371 Flutter Entertainment PLC 25,562,163 Israel - 3.46% (a) 410,426 CyberArk Software, Ltd. 66,320,737 Italy - 1.62% 1,424,162 Azimut Holding SpA 30,916,548 Japan - 12.95% 245,400 GMO Payment Gateway, Inc.
    [Show full text]
  • Oxford Biomedica Delivering Commercial Gene-Therapy Vector
    31st March 2017 Pharmaceuticals & Biotechnology Oxford BioMedica Delivering commercial gene-therapy vector OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties Source: Fidessa on commercial products developed with its LentiVector® platform: extensive IP, facilities, and know-how for production and development of lentiviral vectors to Market data generate gene-based therapies. OXB intends to out-license its five clinical EPIC/TKR OXB candidates and to continue investment in R&D. Bioprocessing royalties are likely Price (p) 5.2 to result in significant upside potential in the near future. 12m High (p) 6.5 12m Low (p) 3.0 ► Strategy: Oxford BioMedica has four strategic objectives: delivery of process Shares (m) 3,088.2 development services which embed its technology in partners’ commercial Mkt Cap (£m) 159.0 products; commercial manufacture of lentiviral vector; out-licensing of EV (£m) 178.1 proprietary candidates; and investment in R&D and the LentiVector platform. Free Float 65% Market LSE ► Revenues: Bioprocessing and process development command fees-for-service, with process development also incurring upfront, milestone and incentive Description payments plus licensing income and royalties on commercial products. Out- Oxford BioMedica is a UK-based licensed candidates will deliver licensing fees plus high royalties if successful. biopharmaceutical company specializing in cell and gene therapies developed using lentiviral vectors, ► Valuation: An EV/sales multiple of 4x prospective sales for the bioprocessing gene-delivery vehicles based on virus and process development services is readily justified, which generates a value particles.
    [Show full text]
  • FTSE Russell Publications
    2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore
    [Show full text]
  • Vectura Group Plc Annual Report and Accounts 2017 Annual Report and Accounts 2017 Accounts and Report Annual
    TRANSFORMING THE LIVES OF AIRWAYS DISEASE PATIENTS Vectura Group plc Vectura Group plc Annual Report and Accounts 2017 Annual Report and Accounts 2017 FAVORITE™ inhalation Our proprietary FAVORITE™ breath controlled nebulised technology, developed to improve effectiveness of inhaled drugs and deliver better clinical outcomes and shorter treatment times ASTHMA Asthma is one of the most common non-communicable diseases.1 Asthma is a chronic, reversible disease that inflames and narrows airways in the lungs, causing wheezing, chest tightness and coughing.2 Not all asthma is the same and severe asthma can have a number of underlying causes.3 Triggers4 Dust mites Pets Sulphites in Infections, such Physical activity, foods and drinks as colds including exercise Symptoms Prevalence • Recurring attacks of breathlessness and wheezing that • Asthma is a significant health burden of considerable vary in severity and frequency from person to person5 and growing significance with increasing urbanisation7 • Asthma attacks – a sudden worsening of symptoms, • Estimated 10m adults under the age of 45 affected in Europe9 can be unpredictable and 18.4m adults in the US9 • During an asthma attack, the lining of the bronchial • Prevalence continues to increase and it is estimated that tubes swell, causing the airways to narrow and by 2025 asthma will affect more than 400m people globally10 6 reducing the flow of air into and out of the lungs • Asthma affects people of all ages but most frequently begins in childhood11 14% of the world’s children experience asthma symptoms12 Impact 40–50% • Patients with uncontrolled asthma are significantly of patients are not well controlled14; poor more likely to suffer from poor outcomes and adherence to treatment and device user errors contribute to lack of control 15 medical emergencies • Asthma caused 383,000 deaths in 201513 By 2025 the total asthma market is expected to be worth over $17bn16 1 Latest WHO estimates, released in December 2016, 9 2014; 12; 24: 14009; Centers for Disease, Control and Prevention (CDC).
    [Show full text]
  • Witan Investment Trust Plc Portfolio Listing As at 31.07.2021
    WITAN INVESTMENT TRUST PLC PORTFOLIO LISTING AS AT 31.07.2021 SECURITY % OF TOTAL INVESTMENT APAX GBL ALPHA NPV 2.98 ALPHABET A USD0.001 1.88 PRINCESS PRIVATE EQTY HLDGS ORD EUR0.001 1.87 ELECTRA PRIVATE GBP 0.25 1.53 SYNCONA ORD NPV 1.34 CHARTER COMMUNICATIONS -A USD0.001 1.32 BLACKROCK WORLD MINING TST ORD GBP0.05 1.31 ARCELORMITTAL NPV 1.30 DIAGEO GBP28.93518 1.27 PAYPAL HLDGS USD0.0001 1.16 INTUIT USD0.01 1.11 HEINEKEN HLDGS EUR1.6 1.08 SCHRODER REAL ESTATE INV TST ORD NPV 1.03 THERMO FISHER SCIENTIFIC USD1 1.02 UNILEVER GBP0.031111 1.00 BT GRP ORD GBP0.05 0.98 NATWEST GRP GBP1 0.91 TAIWAN SEMICONDUCTOR MANUFACTURING 1 ADS REP 5 ORD TWD10 0.89 FACEBOOK A USD0.000006 0.89 FREEPORT-MCMORAN USD0.1 0.89 RELX GBP0.144397 0.86 NATL GRID ORD GBP0.12431289 0.85 LLOYDS BANKING GRP GBP0.1 0.85 VIVENDI EUR5.5 0.82 WALT DISNEY CO USD0.01 0.82 LINDENWOOD USD 0.81 BAE SYSTEMS ORD GBP0.025 0.80 MICROSOFT CORP USD0.00000625 0.79 SHOPIFY A NPV 0.79 CANADIAN PACIFIC RAILWAY NPV 0.77 VINCI EUR2.5 0.77 LONDON STK EXCHANGE GRP GBP0.06918605 0.76 SMURFIT KAPPA GRP EUR0.001 0.76 UNITEDHEALTH GRP USD0.01 0.75 PEPSICO USD0.017 0.74 MONDELEZ INTL USD0.01 0.74 PEARSON GBP0.25 0.70 NINTENDO CO NPV 0.69 LVMH MOET HENNESSY LOUIS VUI EUR0.3 0.68 VH GBL SUSTAINABLE ENERGY NPV 0.67 MOODYS CORP USD0.01 0.67 CRH EUR0.32 0.66 FISERV USD0.01 0.66 LAM RESEARCH CORP COM USD0.001 0.65 BREEDON GRP NPV 0.64 FLUTTER ENT GBP0.09 0.63 SHISEIDO CO NPV 0.63 COOPER COS COM USD0.10 0.63 MASTERCARD A USD0.0001 0.62 MERCADOLIBRE COM USD0.001 0.61 BECTON DICKINSON & CO USD1 0.59 SAFRAN EUR0.20 0.58 ILLUMINA COM USD0.01 0.58 PRYSMIAN EUR NPV 0.57 BAXTER INTL COM USD1 0.56 DELTA AIR LINES USD0.0001 0.55 APPLIED MATERIALS USD0.01 0.55 STRYKER CORP USD0.1 0.54 HARGREAVES LANSDOWN GBP0.004 0.54 SONIC HEALTHCARE NPV 0.53 ADYEN NPV 0.53 CATALENT USD0.01 0.52 WEST PHARMACEUTICAL SERV USD0.25 0.51 INTERCONTINENTAL EXCHANGE GRP USD0.01 0.50 KAO CORP NPV 0.50 TAIWAN SEMICONDUCTOR MANUFACTURING TWD10 0.48 EBAY USD0.001 0.48 REMY COINTREAU EUR1.6 0.48 Please see the disclaimer at the end of this document.
    [Show full text]
  • Phoenix Unit Trust Managers Manager's Interim Report
    PHOENIX UNIT TRUST MANAGERS MANAGER’S INTERIM REPORT For the half year: 2 May 2020 to 1 November 2020 (unaudited) PUTM UK STOCK MARKET FUND (SERIES 3) Contents Investment review 2-3 Portfolio of investments 4-10 Top ten purchases and sales 11 Statistical information 12-14 Statements of total return & change in unitholders’ funds 15 Balance sheet 16 Distribution table 17 Corporate information 18-19 1 Investment review Dear Investor Performance Review Welcome to the PUTM Stock Market Series 3 Unit Trust Over the review period, the accumulation units in the interim report for the six months to 1 November 2020. PUTM Stock Market Series 3 Unit Trust returned 3.35% (Source: SSGA/HSBC for six months to 1/11/20). Over the same period, the FTSE 250 (ex Investment Trusts) Index returned +3.32% (Source: FactSet, FTSE 250 (ex Investment Trusts) Index for six months to 1/11/20). In the table below, you can see how the Fund performed against its benchmark over the last five discrete one-year periods. Standardised Past Performance Nov 19-20 Nov 18-19 Nov 17-18 Nov 16-17 Nov 15-16 % growth % growth % growth % growth % growth PUTM UK Stock Market (Series 3) Unit Trust -16.97 8.69 -5.08 18.76 3.26 FTSE 250 (ex Invt Trust) Index -16.98 8.90 -5.05 19.01 3.55 Source: Fund performance: SSGA and HSBC to 1 November for each year. Benchmark index performance: FactSet, FTSE 250 (ex Invt Trust) Index Total Return, to 1 November for each year.
    [Show full text]